Orgenesis Inc. Stock

Equities

ORGS

US68619K2042

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
0.502 USD -3.28% Intraday chart for Orgenesis Inc. -1.36% +0.26%
Sales 2022 36.02M Sales 2023 530K Capitalization 15.96M
Net income 2022 -14M Net income 2023 -55M EV / Sales 2022 1.8 x
Net Debt 2022 14.96M Net Debt 2023 21.78M EV / Sales 2023 71.2 x
P/E ratio 2022
-3.29 x
P/E ratio 2023
-0.26 x
Employees 146
Yield 2022 *
-
Yield 2023
-
Free-Float 78.99%
More Fundamentals * Assessed data
Dynamic Chart
1 day-3.28%
1 week-1.36%
Current month-38.93%
1 month-44.16%
3 months+63.62%
6 months-41.87%
Current year+0.26%
More quotes
1 week
0.49
Extreme 0.4923
0.53
1 month
0.30
Extreme 0.3044
0.90
Current year
0.25
Extreme 0.25
0.91
1 year
0.25
Extreme 0.25
1.50
3 years
0.25
Extreme 0.25
6.47
5 years
0.25
Extreme 0.25
8.30
10 years
0.25
Extreme 0.25
16.80
More quotes
Managers TitleAgeSince
Founder 70 08-06-04
Chief Executive Officer 55 12-02-01
Director of Finance/CFO 54 Jan. 01
Members of the board TitleAgeSince
Director/Board Member 64 13-07-17
Chief Executive Officer 55 12-02-01
Director/Board Member 54 20-01-08
More insiders
Date Price Change Volume
24-04-24 0.502 -3.28% 34,181
24-04-23 0.519 +2.33% 18,415
24-04-22 0.5072 +1.26% 22,024
24-04-19 0.5009 -2.19% 59,963
24-04-18 0.5121 +0.63% 26,689

Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT

More quotes
Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.
More about the company